HC Wainwright & Co. reiterated coverage on Akero Therapeutics with a new price target

11/15/21 6:45:55 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $62.00 from $64.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKRO

Date	Price Target	Rating	Analyst
1/30/2025	$35.00 → $63.00	Neutral → Buy	BofA Securities
1/27/2025	$50.00 → $72.00	Buy	H.C. Wainwright
11/18/2024	$65.00	Buy	Citigroup
4/22/2024	$30.00	Neutral	BofA Securities
9/19/2023	$69.00	Overweight	Cantor Fitzgerald
8/28/2023	$83.00	Buy	UBS
1/27/2023	$40.00 → $65.00	Equal-Weight → Overweight	Morgan Stanley
9/14/2022	$10.00 → $50.00	In-line → Outperform	Evercore ISI